Asia-Pacific

The Prime objective of “Asia-Pacific Glucagon like Peptide – 1 (GLP – 1) Agonists Market” report is to provides an in-depth analysis of all market dynamics including drivers and restraints, and trends and opportunities. Important factors supporting growth across various is also provided. Using the industrial figures, the market finds growth figures between the forecast period from 2019 to 2024. In order to present an executive-level model of the market and its future perspectives, the report presents a clear segmentation based on different parameters. The factors that affect these segments are also discussed in detail in the report.

Request For Sample Copy of Asia-Pacific Glucagon like Peptide – 1 (GLP – 1) Agonists Market Report @ https://www.industryresearch.co/enquiry/request-sample/13999712

Top Key Players Are:

  • NovoNordisk
  • Sanofi Aventis
  • Eli Lilly
  • Astra Zeneca

    Asia-Pacific Glucagon like Peptide – 1 (GLP – 1) Agonists Market Report Covers the Top Regions:

    United States, Canada, Mexico, Germany, United Kingdom, France, Italy, Spain, China, Japan, India, Australia, South Korea, GCC, South Africa, Brazil, Argentina.

    Scope of Asia-Pacific Glucagon like Peptide – 1 (GLP – 1) Agonists Market:

    The Asia-Pacific region suffers from a high burden of diabetes, and its adverse health and economic consequences.The disease is not only viewed as a serious threat, just from a public health perspective, but also from a development perspective.With risk factors, such as obesity increasing, and progressively aging populations, the diabetes epidemic is growing, especially in the low- and middle-income countries of the region.It is one of the most common chronic diseases in China and India. The market is segmented by drug (Exenatide, Liraglutide, Dulaglutide, Lixisenatide), by brand (Byetta, Bydureon, Victoza, Trulicity, Lyxumia), and by geography.

    Have Any Query, Ask Our Industry Experts @ https://www.industryresearch.co/enquiry/pre-order-enquiry/13999712

    Key Market Trends: – Ever Increasing Prevalence of Diabetes

    China tops the list of countries for the total number of people with diabetes, followed by India. The number of people with diabetes in Japan has also increased significantly.
    According to the IDF in 2013, it is estimated that Japan occupied the 10th position in the IDF list, with 7.2 million people with diabetes.
    WHO projects that diabetes is likely to be the seventh leading cause of death by 2030. Almost half of all deaths attributable to high blood glucose occur before the age of 70 years.
    The growing prevalence of diabetes is the primary driver for the Asia-Pacific diabetes care market. Additionally, rising awareness regarding diabetes care, the ever-increasing prevalence of obesity, and technological advancements are further driving the market.

    Japan is Dominating the GLP-1 Market in the Asia-Pacific Region

    Japan holds the highest share in the Asia-Pacific GLP-1 agonist market, followed by China. GLP-1 receptor agonists have effective glucose-lowering efficacies and remarkable weight-loss effects, and are beneficial for diabetes treatment, especially for patients with overweight/obesity.
    In Asia-Pacific, the revenue generated by the GLP-1 market was USD 384.04 million in 2017, and the market is expected to grow steadily during the forecast period, at a considerable rate of 15.93%. The growth of the market can be attributed to the fact that the type-2 diabetic population is on the rise and is expected to see further increase in the future, due to the lifestyle choices of individuals.
    By brand, Victoza occupies the significant market share, at 62.07%, and it is expected to witness a growth rate of 11.49% during the forecast period. Trulicity held 26.24%, as of 2017.
    Trulicity has a growth rate of 25.48% and is expected to reach almost the same overall market value as of Victoza, by 2024.

    Report Highlights:

    • Market Dynamics – Drivers, Restraints, and Opportunities
    • Market Segmentation – Types, Applications, Regions, and Technology
    • Market Trends
    • Competitive Landscape
    • SWOT Analysis and Porter’s Five Forces Analysis

    Purchase Asia-Pacific Glucagon like Peptide – 1 (GLP – 1) Agonists Market Report @ https://www.industryresearch.co/purchase/13999712

    Price of Report: $ 4000 (SUL)

    Detailed TOC of Asia-Pacific Glucagon like Peptide – 1 (GLP – 1) Agonists Market Research Report 2019 – 2024:

    1 INTRODUCTION
    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study

    2 RESEARCH METHODOLOGY

    3 EXECUTIVE SUMMARY

    4 MARKET DYNAMICS
    4.1 Market Overview
    4.2 Drivers
    4.3 Restraints
    4.4 Porter’s Five Forces Analysis
    4.4.1 Bargaining Power of Suppliers
    4.4.2 Bargaining Power of Consumers
    4.4.3 Threat of New Entrants
    4.4.4 Threat of Substitute Products and Services
    4.4.5 Intensity of Competitive Rivalry

    5 MARKET INDICATORS
    5.1 Type-1 Diabetes Population (2012-2024)
    5.2 Type-2 Diabetes Population (2012-2024)

    6 MARKET SEGMENTATION
    6.1 By Drug
    6.1.1 Exenatide
    6.1.1.1 Byetta (Value and Volume, 2012-2024)
    6.1.1.2 Bydureon (Value and Volume, 2012-2024)
    6.1.2 Liraglutide
    6.1.2.1 Victoza (Value and Volume, 2012-2024)
    6.1.3 Lixisenatide
    6.1.3.1 Lyxumia (Value and Volume, 2012-2024)
    6.1.4 Dulaglutide
    6.1.4.1 Trulicity (Value and Volume, 2012-2024)
    6.2 Geography
    6.2.1 Asia-Pacific
    6.2.1.1 Japan (Value and Volume, 2012-2024)
    6.2.1.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    6.2.1.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    6.2.1.2 China (Value and Volume, 2012-2024)
    6.2.1.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    6.2.1.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    6.2.1.3 Australia (Value and Volume, 2012-2024)
    6.2.1.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    6.2.1.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    6.2.1.4 India (Value and Volume, 2012-2024)
    6.2.1.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    6.2.1.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    6.2.1.5 South Korea (Value and Volume, 2012-2024)
    6.2.1.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    6.2.1.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    6.2.1.6 Malaysia (Value and Volume, 2012-2024)
    6.2.1.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    6.2.1.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    6.2.1.7 Indonesia (Value and Volume, 2012-2024)
    6.2.1.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    6.2.1.7.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    6.2.1.8 Thailand (Value and Volume, 2012-2024)
    6.2.1.8.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    6.2.1.8.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    6.2.1.9 Philippines (Value and Volume, 2012-2024)
    6.2.1.9.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    6.2.1.9.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    6.2.1.10 Rest of Asia-Pacific (Value and Volume, 2012-2024)
    6.2.1.10.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    6.2.1.10.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)

    7 COMPETITIVE LANDSCAPE
    7.1 COMPANY PROFILES
    7.1.1 Novo Nordisk
    7.1.2 Sanofi Aventis
    7.1.3 Eli Lilly
    7.1.4 Astra Zeneca
    7.2 MARKET SHARE ANALYSIS
    7.2.1 Novo Nordisk
    7.2.2 Sanofi Aventis
    7.2.3 Eli Lilly
    7.2.4 Astra Zeneca

    8 MARKET OPPORTUNITIES AND FUTURE TRENDS

    About Industry Research:

    Industry Research is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in-depth market research. We are one of the top report resellers in the market, dedicated to bringing you an ingenious concoction of data parameters.

    Contact Us:

    Name: Ajay More

    Organization: Industry Research

    Phone: +44 20 3239 8187 / +14242530807

    Email: [email protected]

    Our latest Report: Golf GPS Market 2019–Global Industry Analysis, Size, Share, Trends, Market Demand, Growth, Opportunities and Forecast 2025

  • Charles Bevers
    News Reporter